Against cholesterol, fewer statins in Europe

European recommendations to combat the consequences of hypercholesterolemia in primary prevention encourage less use of statins than others. They seem to promote the risk of cardiovascular events.

Researchers at Copenhagen University Hospital have compared the usefulness of five recommendations published since 2013 on the primary prevention of cardiovascular disease, ie prevention before the occurrence of a first cardiovascular event in the context of hypercholesterolemia.
Although based on the same epidemiological data, these five recommendations differ substantially. In particular, concerning the recommended prediction model for cardiovascular diseases, the risk threshold as well as the prescription of statins against the elevation of LDL-cholesterol.
This study is published in the journal Annals of Internal Medicine.

Europe stands out

The researchers conducted an observational study of actual cardiovascular events for 10 years. Subsequently, they worked on a model to estimate the effectiveness of the various recommendations on 45,750 people aged 40 to 75 who did not use statins and did not have cardiovascular disease.
The study shows that the percentage of people eligible for statins is 44% as recommended by the Canadian Cardiovascular Society, 42% for the American College of Cardiology (ACC), and only 15% for European societies. cardiology and atherosclerosis (ESC and EAS).
The estimated percentage of cardiovascular disease that could have been avoided using statins for 10 years is 34% for Canadians, 34% for CCA, and only 13% for Europeans.

It is clear that there is in Europe a suspicion of the patients on the real benefit of the treatments against cholesterol. A negative opinion that affects the way experts analyze scientific data ... or these same experts insist more on the dietary approach.

Video: Statin Misinformation: Mayo Clinic Radio (November 2019).